India, May 31 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap in tardive dyskinesia diagnosis and treatment.
The study's key findings indicate that among residents receiving antipsychotic drugs (APDs), 5.6% were diagnosed with extrapyramidal syndrome (EPS), a term encompassing drug-induced movement disorders for which no universally effective treatment exists. Additionally, 1.1% had a confirmed diagnosis of tardive dyskinesia.
The most common comorbidities observed in residents on antipsychotic drugs at risk for TD included dementi...